Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type 2 diabetes. The efficacy and safety of once-weekly tirzepatide as compared with semaglutide, a selective GLP-1 receptor agonist, are unknown. METHODS: In an open-label, 40-week, phase 3 trial, we randomly assigned 1879 patients, in a 1:1:1:1 ratio, to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or semaglutide at a dose of 1 mg. At baseline, the mean glycated hemoglobin level was 8.28%, the mean age 56.6 years, and the mean weight 93.7 kg. The primary end point was the change in the glycated hemoglobin level from baseline to 40 weeks. RESULTS: The estimated mean change from baseline in the glycated hemoglobin level was -2.01 percentage points, -2.24 percentage points, and -2.30 percentage points with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and -1.86 percentage points with semaglutide; the estimated differences between the 5-mg, 10-mg, and 15-mg tirzepatide groups and the semaglutide group were -0.15 percentage points (95% confidence interval [CI], -0.28 to -0.03; P = 0.02), -0.39 percentage points (95% CI, -0.51 to -0.26; P<0.001), and -0.45 percentage points (95% CI, -0.57 to -0.32; P<0.001), respectively. Tirzepatide at all doses was noninferior and superior to semaglutide. Reductions in body weight were greater with tirzepatide than with semaglutide (least-squares mean estimated treatment difference, -1.9 kg, -3.6 kg, and -5.5 kg, respectively; P<0.001 for all comparisons). The most common adverse events were gastrointestinal and were primarily mild to moderate in severity in the tirzepatide and semaglutide groups (nausea, 17 to 22% and 18%; diarrhea, 13 to 16% and 12%; and vomiting, 6 to 10% and 8%, respectively). Of the patients who received tirzepatide, hypoglycemia (blood glucose level, <54 mg per deciliter) was reported in 0.6% (5-mg group), 0.2% (10-mg group), and 1.7% (15-mg group); hypoglycemia was reported in 0.4% of those who received semaglutide. Serious adverse events were reported in 5 to 7% of the patients who received tirzepatide and in 3% of those who received semaglutide. CONCLUSIONS: In patients with type 2 diabetes, tirzepatide was noninferior and superior to semaglutide with respect to the mean change in the glycated hemoglobin level from baseline to 40 weeks. (Funded by Eli Lilly; SURPASS-2 ClinicalTrials.gov number, NCT03987919.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationDavies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Self-citationGlucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Self-citationCoskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882
Self-citationFrias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815
Self-citationPratley, R. E., Aroda, V. R., Lingvay, I., Lüdemann, J., Andreassen, C., Navarria, A., & Viljoen, A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30024-x · Cited by 790
Sorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745
Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2018) · Diabetes Care · doi:10.2337/dc17-0417 · Cited by 596
Cited by
Items 1,701–1,800 of 2,039
Cardiovascular Pharmacotherapy and Glucose Metabolism: The Good, the Bad and the Unsightly
Bianchettin, R. G., Poirier, P., López-Jiménez, F. A., Lavie, C. J., & Piché, M. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00777-2 · Cited by 1
Drugs used in the management of hyperglycaemia
McGregor, P., Lynch, E., & Llano, A. (2025) · Anaesthesia & intensive care medicine · doi:10.1016/j.mpaic.2025.10.011
Clinical Outcomes in the Patient With Traumatic Brain Injury and Comorbid Obesity: A Scoping Review
Eagle, S. R., & Kershaw, E. E. (2025) · Obesity Reviews · doi:10.1111/obr.70040
“The massive influx of studies on glucagon-like peptide-1 receptor agonists, such as semaglutide and tirzepatide, and their anti-inflammatory properties is an intriguing avenue for future work in the TBI population [62–64].”
GLP-1 and GIP/GLP-1 receptor agonists for type 2 diabetes
Morris, D. (2025) · Independent Nurse · doi:10.12968/indn.2025.10.24 · Cited by 1
Ritzel, R. A., Davies, M. J., Hao, L., Ji, L., Lintu, M. K., Mabunay, A., Mauricio, D., & Bailey, T. S. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01798-5
“Tirzepatide has demonstrated improved glycemic control plus a considerable body weight reduction in people with T2D versus GLP-1 RA [5] or basal insulin [6, 7].”
Self-citationBennett, K. A., Gouleguine, R., Sutherland, C. D., & Savage, A. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117575
Andrade, L. J. D. O., de Oliveira, L. C. M., Ramos, L. L. D. S., de Oliveira, G. C. M., & de Oliveira, L. M. (2025) · Research Square · doi:10.21203/rs.3.rs-8214757/v1
Quinaglia, T., Silva, G., Matos‐Souza, J. R., Coelho‐Filho, O. R., Nadruz, W., & Sposito, A. C. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01368-x
“Emerging evidence from studies with dual gastric inhibitory polypeptide (GIP) and GLP-1 receptor agonists suggests even more pronounced effects on cardiovascular biomarkers, including greater reduc - tions in inflammatory markers and improved cardiac met - abolic indices [9, 10 ].”
Pharmacological progress in obesity: tirzepatide’s rising advantage over semaglutide
Khan, S., Afridi, H., Mahato, R. K., Zubair, M., Khan, U., & Ullah, S. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000004507 · Cited by 1
“Additionally, patients treated with tirzepatide exhibited lower triglyceride and serum very-low-density lipoprotein (VLDL) levels, alongside higher high-density lipoprotein (HDL) cholesterol levels compared to those treated with semaglutide [ 5 ] .”
Exploring the unknown territory of gut–brain axis in type 2 diabetes mellitus patients
Rahim, S., & Karim, M. M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33355-2.00007-4
Peptide drugs for obesity and type 2 diabetes mellitus: an overview of clinical trials
Barzgar, H., Darmadi, D., Nafisa, J., Narkulov, S., & Sviridova, M. B. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120772 · Cited by 2
Deng, Z., Zheng, D., Son, J., Du, W. J., McKimpson, W. M., Liu, Q., & Accili, D. (2025) · Acta Physiologica · doi:10.1111/apha.70141
“In this study we investigated two representative GLP-1 and GIP/ GLP-1 receptor agonists with proven clinical effectiveness and differential modes of action to evaluate their effects on β-cell identity [32], independent of their weight loss but dependent on their glucose-lowering effect [33].”
Alvarez, G., Veliz, L., Michaels, S., Pino, D., & Wu, J. (2025) · Obesities · doi:10.3390/obesities5040090 · Cited by 1
“It is more effective than GLP-1 RA alone in regulating appetite and energy consumption, resulting in more weight reduction [8,9].”
GLP-1 and GIP analogues in the treatment of obesity – Current State of Knowledge
Grycan, M., Grycan, G., & Pstrągowski, M. (2025) · Biuletyn Głównej Biblioteki Lekarskiej · doi:10.2478/bgbl-2025-0015
Eisa, N., & Barood, O. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.11.018 · Cited by 3
Zhou, Q., Lei, X., Fu, S., Liu, P., Long, C., Wang, Y., Li, Z., Xie, Q., & Chen, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26633796
Sachs, S., Goetz, A., Finan, B., Feuchtinger, A., DiMarchi, R. D., Döring, Y., Weber, C., Tschöp, M. H., Müller, T. D., & Hofmann, S. M. (2024) · Figshare · doi:10.6084/m9.figshare.26611103
Additional file 1 of Tirzepatide prevents neurodegeneration through multiple molecular pathways
Fontanella, R. A., Ghosh, P., Pesapane, A., Taktaz, F., Puocci, A., Franzese, M., Feliciano, M. F., Tortorella, G., Scisciola, L., Sommella, E., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26674158
Lingvay, I., Mosenzon, O., Brown, K. E., Cui, X., O’Neill, C., Landó, L. F., & Patel, H. (2024) · Figshare · doi:10.6084/m9.figshare.26577536
Self-citationSachs, S., Goetz, A., Finan, B., Feuchtinger, A., DiMarchi, R. D., Döring, Y., Weber, C., Tschöp, M. H., Müller, T. D., & Hofmann, S. M. (2024) · Figshare · doi:10.6084/m9.figshare.26611100
Nicholls, S. J., Tofé, S., le Roux, C. W., D’Alessio, D. A., Wiese, R. J., Pavo, I. J., Brown, K. E., Weerakkody, G. J., Zeytinoglu, M., & Romera, I. (2024) · Figshare · doi:10.6084/m9.figshare.25201920
Self-citationLingvay, I., Mosenzon, O., Brown, K. E., Cui, X., O’Neill, C., Landó, L. F., & Patel, H. (2024) · Figshare · doi:10.6084/m9.figshare.26577542
Self-citationLingvay, I., Mosenzon, O., Brown, K. E., Cui, X., O’Neill, C., Landó, L. F., & Patel, H. (2024) · Figshare · doi:10.6084/m9.figshare.26577539
Self-citationSachs, S., Goetz, A., Finan, B., Feuchtinger, A., DiMarchi, R. D., Döring, Y., Weber, C., Tschöp, M. H., Müller, T. D., & Hofmann, S. M. (2024) · Figshare · doi:10.6084/m9.figshare.26611097
Alshaikh, A., Alshehri, A. A., Elbadawi, H., Aldawish, M., Abalkhail, F., Alsabaan, F., Alaqeel, M., Alotaibi, M., Aljuraibah, F., Wabel, A. A. A., et al. (2025) · International Journal of Clinical Medicine · doi:10.4236/ijcm.2025.1612042 · Cited by 1
A consensus statement from the European Society for Clinical Investigation
Carbone, F., Després, J., Ioannidis, J. P. A., Neeland, I. J., Garruti, G., Busetto, L., Liberale, L., Ministrini, S., Vilahur, G., Schindler, T. H., et al. (2025) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
LATEST ADVANCES IN INJECTABLE AND ORAL MEDICATIONS FOR TYPE 2 DIABETES TREATMENT
Jurkiewicz, K., Ciechański, M., Kasprzyk, A., Wilk, K., Witkowska, E., Cholewiński, S., Wilk, B., Stachura, P., Rejman, P., & Pszczoła, K. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3883
Aloufi, L. K., Almaysari, R. K., Aljehani, A. T., Almalki Dhaifallah Mohammed, D., & Alnefaie, Z. M. (2025) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20254166
Xenin-Derived Peptides: Multifaceted Regulators and Therapeutic Innovations in Metabolic Diseases
Gong, B., Liu, X., Hu, G., Li, T., Chen, F., Sun, X., Sun, L., & Xu, Y. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s565077 · Cited by 1
Chiquette, E., Thisted, L., Feigh, M., Daly, S., Besser, J., & MAGGS, D. G. (2025) · Obesity Medicine · doi:10.1016/j.obmed.2025.100681
Harnessing the gut-brain axis in the treatment of type 2 diabetes mellitus and obesity
Kotucha, K., Kapłon, K., Moś, M., Fiegler-Rudol, J., Pietryszyn-Bilińska, A., Dynarowicz, K., Aebisher, D., Wiench, R., & Kawczyk‐Krupka, A. (2025) · European Journal of Clinical and Experimental Medicine · doi:10.15584/ejcem.2025.4.24
“86-89 The phase III SURPASS trials demonstrated that tirzepatide, both as monotherapy and as adjunctive therapy, is more effective in lowering blood glucose and insulin levels compared with GLP-1RAs.”
Muzammil, M., & Riyaz, M. (2025) · Telangana journal of IMA. · doi:10.4103/tjima.tjima_31_25
Steven, C., Skylynn, T., Bardya, H., Megha, B., Helen, V., Lee, D., Entabi, F., & Pemminati, S. (2026) · Cureus · doi:10.7759/cureus.100704 · Cited by 2
TIRZEPATIDE - A NEW ERA IN OBESITY TREATMENT? A REVIEW OF THE CURRENT STATE OF KNOWLEDGE
Solarz, A., Kryślak, J., Szabelski, S., Graczyk, E., Sokołowski, M., & Oskroba, K. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(48).2025.4143
Research progress in precision medicine for type 2 diabetes based on the GLP-1
Wang, S., Yuan, C., Wang, H., Ye, X., Ruan, S., Yi, L., Yang, W., Wang, Z., Wang, N., Li, J., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1721842 · Cited by 2
Treatment Modalities for Hepatic Steatosis and Fibrosis in Type 2 Diabetes: A Review Article
Damle, V. A., Sharma, A., Srivastava, B. K., Raveendran, A. V., Seshadri, K. G., & Mohan, V. (2026) · Journal of Diabetology · doi:10.4103/jod.jod_85_25
Wang, Y., Chu, Z., Li, A., Umoru, D. O., Tran, A., Tian, B., Dou, P., & Moin, T. (2026) · Research Square · doi:10.21203/rs.3.rs-8546087/v1
Sraboni, A., Farhana, K. M., & Abdul, M. K. (2026) · Review of Medicine Surgery and Dentistry · doi:10.64907/xkmf.v5.i1.rmsd.1
Robinson, K. M., Rodriguez, S. A., Pedagarla, C., Eyck, P. T., Correia, M. L., & Dokun, A. O. (2026) · Obesity Science & Practice · doi:10.1002/osp4.70114 · Cited by 1
ONE DRUG TO FIX IT ALL? THE ROLE OF TIRZEPATIDE IN TREATING COMPONENTS OF METABOLIC SYNDROME
Tomasiczek, S., Tomasiczek, W., Kondyjowska, D., Sawiec, Z., Bukała, N., Komuńska, D. M., Antonowicz, E., & Rogozińska, M. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(48).2025.4180
Fu, L., Fan, J., Yue, X., Yang, S., Xie, X., & Zhong, J. (2026) · Medical Research Frontiers · doi:10.57237/j.mrf.2025.04.001
Parikh, M., Pu, J., Shen, J., et al. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag033
A potent novel small molecule GLP-1R agonist identified by rational design and CADD
Chen, J., Yao, Y., & Li, H. (2026) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2026.118578 · Cited by 1
Tong, J., Li, N., Hu, F., & Yue, Y. (2026) · European journal of medical research · doi:10.1186/s40001-026-03986-w
Anti-obesity drugs: comprehensive review and emerging therapies
Marne, P., Patil, S. D., Vora, A., MohdSiddique, M. U., Gadkari, Y. U., & Kurkute, P. (2026) · Endocrine · doi:10.1007/s12020-025-04528-w · Cited by 1
Bednarczyk, R., Bednarczyk, N., Binkowski, R. K., Kurek, A., Krajewska, N., Lejman, A., Mazurkiewicz, A., Sidor, H., Wołosik, M., & Zysiak, S. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.1(49).2026.4671
Indennidate, C., Perencin, B., Maso, V. D., Buda, I., Candido, R., Sinagra, G., & Merlo, M. (2026) · Current Cardiology Reports · doi:10.1007/s11886-025-02340-6 · Cited by 1
“Among the newer agents, tirzepatide—a dual GIP and GLP-1 receptor agonist—has shown remarkable efficacy in both glycemic control and weight loss, achieving weight reductions exceeding 20% in the SURPASS trial [ 65].”
Perioperative Medication Management for Patients with Diabetes
Duggan, E. W., & Mazer, C. D. (2026) · Medical Clinics of North America · doi:10.1016/j.mcna.2025.11.010 · Cited by 1
Targeting GLP1 receptor for reducing global cardiovascular risk
Curcio, A., Meringolo, F., Marincolo, C., Polimeni, A., & Costanzo, S. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-07736-8 · Cited by 2
Gerdes, C., & Wolf, G. (2026) · Diabetes aktuell · doi:10.1055/a-2759-5230
Oliveira-Gomes, D. D., de Majo, A. M., Ardila-Delgado, A. D., Inglis, S. S., Mandras, S. A., Loro-Ferrer, J. F., & daSilva‐deAbreu, A. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01395-2
“…in glycated hemoglobin (mean change from baseline from − 2.01% to − 2.30% across doses vs. − 1.86% with semaglutide) and in body weight (placebo-adjusted dif - ferences of − 1.9 to − 5.5 kg), thereby demonstrating superi - ority over semaglutide for both glycemic and weight control [49 ].”
InfluentialEl‐Amawy, H. S. (2026) · Anais Brasileiros de Dermatologia (Versão em Português) · doi:10.1016/j.abdp.2026.501255 · Cited by 1
Tirzepatide improves pancreatic β-cell function in mice and patients with type 2 diabetesPreprint
Li, Z., Guo, J., Cheng, Y., Zhang, T., Luo, X., Zhang, S., Ren, Q., Wu, Z., Chen, N., & Li, M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.13.704343
Monnier, L., Schlienger, J.-L., & Colette, C. (2026) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2026.02.002
Treatment of obesity: New drugs
Berti, S., Garelli, S., & Pagotto, U. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00330-7
Jensen, A. B., Renström, F., & Brändle, M. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.106787
Adverse events associated with tirzepatide: a focus on subgroup-specific differences
Yu, Z., Qi, Y., Gan, Q., Wu, G., Zhang, X., Jiang, C., & Li, J. (2026) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-026-01105-3 · Cited by 3
“Clinical trial data indicate that 1.9-8.0% of tirzepatide-treated patients experienced injection site reactions [47, 48].”
InfluentialMedikamentöse Therapie der Adipositas
Malzner, A. (2026) · Journal für Gastroenterologische und Hepatologische Erkrankungen · doi:10.1007/s41971-026-00250-0
Yang, Y., Liu, Z., HUANG, Y. ‐., Deng, H., Yang, X., Yan, J., Zeng, L., Lin, B., & Xu, W. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-026-02204-2 · Cited by 2
“Both TIR and TITR emerged as valuable indicators, with TITR potentially offering a more stringent target reflecting near-normoglycemia achievable with modern therapies like automated insulin delivery and potent incretin-based agents [28, 29].”
(2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33287-6.00006-5
Treatment Decision-making and Weight Loss Expectations for Current Obesity Treatment
Paknikar, S. S., & Shah, M. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00691-x
Kanumilli, N., Osumili, B., Evans, J., Webb, J., Buckingham, M., Debackere, N., Nowakowski, P., Cattin, J., & Hunt, B. (2026) · Journal of Medical Economics · doi:10.1080/13696998.2026.2631920
Schulz, M., Studzinski, D., & Kołcz, A. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(48).2025.4276 · Cited by 1
Saldívar-Cerón, H. I. (2026) · Scientia Pharmaceutica · doi:10.3390/scipharm94010021
“Gastrointestinal adverse events remain the dominant side effects of GLP-1-based therapies and are closely related to dose and speed of titration [33,55,56].”
Pharmacological and Surgical Interventions That Prevent or Remit Type 2 Diabetes
Neeland, I. J., & Baskin, R. L. G. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00004-5
Effect of Blood Pressure Management on Coronary Heart Disease Risk in Patients With Type 2 Diabetes
Arnott, C. G., & Patel, A. A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00018-5
Reshaping Decision‐Making Through Evidence‐Based Medicine Content Alignment With Pharmacotherapy
Bowers, B. L., Sperry, M. L., Englin, E. F., et al. (2026) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.70193
Khatib, O. E., Chiha, M., Jarad, O., Salloum, C., Baba, K. E., Dajani, R., Shaqfa, S. A., & Hajj, S. E. (2026) · Experimental and Clinical Transplantation · doi:10.6002/ect.2025.0180 · Cited by 1
ABBA, V., Nielsen, A. B. E., Buhr, P., Hammelev, K. P., Holst, J. J., & Lobato, C. B. (2026) · Anesthesia Research · doi:10.3390/anesthres3010006
Hoog, M. M., Minghetti, A., & Valentine, W. J. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01846-8 · Cited by 1
Tirzepatide and semaglutide: different twins?
Cesaro, A., Acerbo, V., & Calabrò, P. (2026) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suag028
Eisa, N., & Barood, O. (2026) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2026.03.003 · Cited by 1
Li, D., Smith, A. J., & Marra, C. A. (2026) · Clinical Drug Investigation · doi:10.1007/s40261-026-01530-6 · Cited by 2
Singh, S., Kumar, R., Maharshi, V., Sinha, N., & Payra, S. (2026) · Indian Journal of Physiology and Pharmacology · doi:10.25259/ijpp_357_2025
Wilkinson, T. J., Biddle, G. J. H., & James, E. (2026) · The Nephron journals/Nephron journals · doi:10.1159/000551510
“GLP-1RAs and regular exercise share several mechanistic targets, particularly in appetite regulation, inflammation, and weight loss [51, 52].”
Medenica, S., Prelević, V., Zanković, N., Maggio, V., & Rizzo, M. (2026) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2026.2648248 · Cited by 1
Thirugnanam, A. M., Chandrakanth, & Pruthvi (2026) · Cardiovascular revascularization medicine · doi:10.1016/j.carrev.2026.03.011
Khan, O. O., & Shah, S. B. A. (2026) · Research Square · doi:10.21203/rs.3.rs-9079798/v1
Chawla, R., Jaggi, S., Chawla, Y., Jaggi, C., Chawla, S., & Trehan, S. (2026) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-026-01645-8
Liuzzo, G., & Patrono, C. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag194
Mitchell, S., Patwardhan, K., Lucocq, J. E., Geropoulos, G., Lamb, P., Ghanem, O. M., Stimson, R. H., & Robertson, A. G. (2026) · Diabetic Medicine · doi:10.1111/dme.70305
Violante-Ortiz, R. M., Rose, L., Sharma, P., Valderas, E. G., Chivukula, K. K., & Kwan, A. Y. M. (2026) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005711 · Cited by 1
“17 18 18–23 In a post hoc analysis of the SURPASS-1 to SURPASS-5 trials, a composite outcome of glycemic control (HbA1c ≤ 6.5”
InfluentialCiarloni, A., Salvio, G., Bordoni, M., Giacchetti, G., & Balercia, G. (2026) · Biomedicines · doi:10.3390/biomedicines14040778
“That treatment can lead up to 20–22.5% weight reduction [17], similarly to bariatric surgery [18].”
InfluentialTirzepatide in Egypt: A New Era in Type 2 Diabetes and Obesity Management
Ghazi, H. A. (2026) · doi:10.5005/jodec-11035-0006 · Cited by 1
Agrawal, P. K., Samajdar, S. S., Garg, R., Gupta, G., Gautam, A., Husain, N., Mukherjee, S., & Panda, S. K. (2026) · Journal of Mid-life Health · doi:10.4103/jmh.jmh_373_25
Afanaseva, A. N., Saparova, V. B., Ermolaeva, D. О., Makarenko, I. E., & Васильевич, Д. Р. (2026) · Drug development & registration · doi:10.33380/2305-2066-2026-15-2-2145
Jarso, G., Mahendru, S., Dutta, A., Sharma, R., Megerso, A., & Mithal, A. (2026) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_1085_25
“[9,10] Moreover, our finding aligns with real‑world studies reporting weight losses of 9.4% and 12.2% at 6 and 12 months, respectively.”
InfluentialMechanism of GLP-1 Receptor Agonists in Weight Loss through Appetite Suppression
姚, 张. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1641386
Chashchin, M. G., Velichko, A. M., Glechyan, A. M., Emelyanov, A. V., Gorshkov, A. Y., & Drapkina, O. M. (2026) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2026-3246
Clinical Potential of GIP in Type 2 Diabetes and Obesity
Nauck, M. A., Gribble, F. M., Reimann, F., D’Alessio, D. A., & Campbell, J. E. (2026) · Diabetes Care · doi:10.2337/dci25-0141 · Cited by 3
iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · International Journal of Cardiovascular Sciences · doi:10.36660/ijcs.20260056
Self-citationZarówna, K., Pura, W., Mazur, J., Marciniak, J., Kosowski, M., Matecka, D., Śliwiński, W., & Chołuj, D. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.1(49).2026.4791
Tirzepatide versus dulaglutide in heart failure: another SURPASS attempt yielding a tie
Busti, M. D., Canonico, M. E., Keramida, K., Palazzuoli, A., Kato, E. T., Sakata, Y., Alexy, T., Grupper, A., Nodari, S., Ojji, D. B., et al. (2026) · Heart Failure Reviews · doi:10.1007/s10741-026-10627-1
Adamidis, N., Adamidi, S., GEORGAKOPOULOU, V. E., & Adamidis, S. (2026) · Cureus · doi:10.7759/cureus.107073
“Tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has demonstrated significant efficacy in improving glycemic control, promoting weight loss, and reducing cardiometabolic risk factors [14,15].”
Increased Levothyroxine Requirement After Tirzepatide Initiation
Koç, D., & Keskinler, M. V. (2026) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2026.04.007 · Cited by 1
Svechnikova, E. V. S., Zhufina, S. Е., & Morzhanaeva, M. A. (2026) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2026-091
Tudosie, A. C., Marin, L.-M., Popa, S. G., & Golli, A. L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083628 · Cited by 2
Awadalla, L., Iskander, S., Chu, C., & Tadrous, M. (2026) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0248 · Cited by 1
Metadata
- Authors
- Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K.
- Affiliations
- University of Leicester (GB)
- From the National Research Institute, Los Angeles (J.P.F.); the Diabetes Research Centre, University of Leicester, and the National Institute of Health Research Leicester Biomedical Research Centre — both in Leicester, United Kingdom (M.J.D.); the Dallas Diabetes Research Center at Medical City, Dallas (J.R.); Centro de Investigaciones Metabólicas, Buenos Aires (F.C.P.M.); and Eli Lilly, Indianapolis (L.F.L., B.K.B., B.L., X.C., K.B.).
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-08-05
- Volume
- 385
- Issue
- 6
- Pages
- 503-515
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3177122952
- Cited by
- 2,096
- References
- 25
- Citations by year
- 2026: 526 · 2025: 556 · 2024: 396 · 2023: 351 · 2022: 208 · 2021: 57
- FWCI
- 188.92
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- semaglutide, type 2 diabetes, HbA1c, GLP-1 receptor agonists, GIP/GLP-1 dual agonist, non-inferiority, weight loss, gastrointestinal adverse effects, drug safety, dose comparison, glycemic control, adverse drug reactions, hypoglycemia
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Semaglutide, Blood Glucose, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Glucagon-Like Peptides, Female, Gastric Inhibitory Polypeptide, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Metformin, Middle Aged, Nausea, Weight Loss, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.